Rituximab in combination with chop improves survival in elderly patients with aggressive non-Hodgkin's lymphoma

Tumori

Volumn 88, Issue SUPPL. 1, 2002, Pages

  Coiffier, Bertrand ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; VINDESINE;

AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; GERIATRIC DISORDER; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0036194012     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160208800108     Document Type: Conference Paper

References (10)

1. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma. A multicenter phase II study
2. Rituximab plus CHOP (R-CHOP) in the treatment of elderly patients with diffuse large B-cell lymphoma. An update of the GELA study
3. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
4. IDEC-C2B8 (rituximab) anti-CD-20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
5. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
6. Randomised phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma
7. Comparison of doxorubicin and mixantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy
8. The Non-Hodgkin's Lymphoma Classification Project: Effect of age on the characteristics and clinical behaviour of non-Hodgkin's lymphoma patients
9. A randomised comparison of ACVBP and CHOP in the treatment of advanced aggressive non-Hodgkin's lymphoma: The LNH93-5 study
10. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma